Program Status
Active, not recruitingPhase
Phase 2Prior Immunotherapy Allowed
YesCRC-directed Trial
YesDrugs
Cetuximab Injection [Erbitux], HLX208Tags
MSS/ MMRpComments
For BRAF mutant CRC, after failure of first line treatment. Targeted therapy.
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer (and head and neck cancer). It is mainly used in KRAS wild type metastatic CRC.
HLX208 – trial medication that is a BRAF V600E Inhibitor
Location | Location Status |
---|---|
China | |
Fudan University Affiliated Oncology Hospital Shanghai |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
Age>=18Y
Good Organ Function
Expected survival time ≥ 3 months
Metastatic/recurrent advanced BRAF+ mCRC that have been diagnosed histologically and have failed first line treatment
ECOG score 0-1;
Exclusion Criteria
Exclusion Criteria:
arm 1 : Previous treatment with BRAF inhibitors or MEK inhibitors
Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
Active clinical severe infection;
A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.